Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462118 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT06462118 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 78 participants.
The verdict
NCT06462118, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
The main objective is to study how astegolimab may behave in the body when injected subcutaneously into the abdomen, thigh, or upper arm in healthy participants.
Interventions
- DRUG Astegolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2024-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06462118
The ClinicalTrials.gov registry entry for NCT06462118 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Astegolimab is the first listed.
NCT06462118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06462118 about?
NCT06462118 is a clinical study titled "A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects". The main objective is to study how astegolimab may behave in the body when injected subcutaneously into the abdomen, thigh, or upper arm in healthy participants.
What is the current status of trial NCT06462118?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2024-06-17. Estimated completion is 2024-10-22.
What interventions are being tested in trial NCT06462118?
The interventions under investigation include: Astegolimab (DRUG).
Who is sponsoring clinical trial NCT06462118?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.